Facebook Instagram X-twitter Linkedin

AOD 9064 (2mg)

Table of Contents

  • Quickstart Highlights

AOD 9604 – 2mg protocols focus on this modified fragment of human growth hormone (HGH 176–191), designed to specifically target fat metabolism without the broader systemic effects associated with full HGH. It is studied for its potential role in promoting lipolysis (fat breakdown) and inhibiting fat storage. This guide outlines a subcutaneous administration approach optimized for the 2 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 2 mg/mL concentration
  • Typical daily range: 200–500 mcg per day (subcutaneous)
  • Easy measuring: At 2 mg/mL, 1 unit = 0.01 mL = 20 mcg (0.02 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support fat metabolism and lipolysis without affecting blood glucose or IGF-1 levels
  • Schedule: Daily subcutaneous injections
  • Dose Range: 200–500 mcg per day
  • Cycle Length: Commonly used in 4–12 week cycles depending on goals
  • Dosing Protocol

Suggested approach for the 2 mg vial format.

  • Start: 200 mcg once daily to assess response
  • Target: 300–500 mcg once daily
  • Frequency: Once per day (subcutaneous)
  • Vial Duration: One 2 mg vial typically lasts 4–10 days, depending on dose
  • Timing: Morning or pre-activity dosing is often preferred for metabolic support
  • Mechanism of Action

AOD 9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone (HGH 176–191). Unlike full HGH, it does not significantly affect growth pathways, insulin sensitivity, or IGF-1 levels.

Instead, it is believed to act specifically on fat metabolism pathways by stimulating lipolysis (breakdown of stored fat) and inhibiting lipogenesis (formation of new fat cells). Preclinical research suggests it may mimic some fat-reducing effects of growth hormone without the anabolic or endocrine side effects associated with full HGH therapy.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May support the reduction of body fat
  • May enhance fat metabolism and lipolysis
  • Does not significantly impact IGF-1 or blood sugar in studies
  • Considered more targeted compared to full HGH pathways

Possible Side Effects:

  • Mild injection-site irritation
  • Occasional headache or nausea in some reports
  • Limited large-scale human clinical data are available
  • Long-term safety profile not fully established; remains investigational